Table 2.

Synopsis of recommendations from recent selected independent and NIH sponsored multidisciplinary panels and working groups for enhancing the population sciences agenda in cancer translational genomics

President's Council of Advisors on Science and Technology (66)Identify scientific priorities for personalized medicineIntegrated nationwide network of standardized biospecimen repositories, research for validating clinical utility, large U.S. population cohort study investigating genetic and environmental health impacts (selected recommendations)
Institute of medicine report on cancer biomarkers (67)Review cancer biomarker research, development and implementationDevelop high quality biorepositories in prospectively collected samples, create well-defined consensus standards and guidelines for biomarker development validation and use, establish high quality population-based assessments of efficacy and cost-effectiveness of biomarker tests (selected recommendations)
Institute of medicine report on CER (68)Establish a definition of CER and a national top 100 priority listCompare the effectiveness of adding new biomarkers (including genetic information) with standard care in motivating behavior change and improving clinical outcomes; compare the effectiveness of genetic and biomarker testing and usual care in preventing and treating breast, colorectal, prostate, lung, and ovarian cancer (selected recommendations)
NIH-CDC (69)Enhancing the scientific foundation for using genetic risk profiles in risk assessment and disease preventionDevelop scientific standards for personal genomic tests; enhance multidisciplinary population research; enhance credible knowledge synthesis and dissemination to providers, consumers and policy makers; explore the value of personal utility of genetic information
NCI pharmacoepidemiology and pharmacogenomics working group (70)Setting a research agenda in pharmacoepidemiology and pharmacogenomics to accelerate translationDevelop and support a knowledge synthesis study group; support observational studies that assess genomic and nongenomic factors affecting treatment response and adverse effects; support research on the utility of promising pharmacogenomic applications in practice; support efforts that integrate basic, clinical and population research
NHGRI multidisciplinary panel (71)Priorities for behavioral, social and communications researchResearch to improve the public's genetic literacy to enhance consumer skills, assess if genomic information improves risk communication and adoption of healthy behaviors more than currentapproaches, explore if genomics can lead to new behavioral intervention targets, consider multiple levels of influence that contribute to public health problems
NCI workshop (72)Examine the state of health services research in cancer cellular, molecular and genomic technologies; identify priorities for expanding knowledge baseDevelopment of a comprehensive research agenda on health and safety endpoints, utilization patterns, patient and provider preferences, quality of care and access, disparities, economics and quality of life
NCI genomics and personalized medicine CER methods working group (Goddard, in preparation)Identify CER approaches that can be employed to answer questions about cancer genomic applications faced by various stakeholdersSeveral CER approaches can be applied to cancer genomics including evidence generation and synthesis, stakeholder engagement, in trials and observational studies; decision modeling and economic analyses